Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Hematologic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05801939
What this trial is testing

Cevostamab Following CAR T Cell Therapy for RRMM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
University of Pennsylvania 30
Testing effectiveness (Phase 2)Study completedNCT03450057
What this trial is testing

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Hellenic Society of Hematology 38
Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Large-scale testing (Phase 3)UnknownNCT05006469
What this trial is testing

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Who this might be right for
BendamustineMultiple Myeloma
Liao Aijun 10
Very early researchUnknownNCT06067581
What this trial is testing

The Safety and Efficacy of SENL103 Autologous T Cell Injection

Who this might be right for
Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06235229
What this trial is testing

GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd. 110
Large-scale testing (Phase 3)Study completedNCT01147939
What this trial is testing

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Clavis Pharma 381
Testing effectiveness (Phase 2)Ended earlyNCT03176277
What this trial is testing

ONO-7475 in Patients With Acute Leukemias

Who this might be right for
Acute LeukemiaMyelodysplastic Syndromes
Ono Pharmaceutical Co., Ltd. 42
Very early researchWithdrawnNCT07338357
What this trial is testing

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

Who this might be right for
AML (Acute Myeloid Leukemia)CAR-T
First Affiliated Hospital of Guangxi Medical University
Early research (Phase 1)WithdrawnNCT06411301
What this trial is testing

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Who this might be right for
Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression
Jules Bordet Institute
Testing effectiveness (Phase 2)Ended earlyNCT00112723
What this trial is testing

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more
National Cancer Institute (NCI) 46
Large-scale testing (Phase 3)Ended earlyNCT02576977
What this trial is testing

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC 251
Testing effectiveness (Phase 2)Active Not RecruitingNCT03277729
What this trial is testing

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+20 more
Fred Hutchinson Cancer Center 53
Early research (Phase 1)Ended earlyNCT04250051
What this trial is testing

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative Neoplasm+5 more
Northwestern University 2
Early research (Phase 1)Looking for participantsNCT05188170
What this trial is testing

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Who this might be right for
Acute Myeloid Leukemia (AML)
Stanford University 16
Testing effectiveness (Phase 2)UnknownNCT04913922
What this trial is testing

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

Who this might be right for
Acute Myeloid Leukemia
Ludwig-Maximilians - University of Munich 30
Very early researchWithdrawnNCT05015972
What this trial is testing

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

Who this might be right for
B-cell Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Early research (Phase 1)Looking for participantsNCT07369895
What this trial is testing

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., Limited 18
Testing effectiveness (Phase 2)Looking for participantsNCT05092451
What this trial is testing

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Who this might be right for
B-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT01589302
What this trial is testing

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Who this might be right for
Prolymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory/Relapsed Chronic Lymphocytic Leukemia
Kami Maddocks, MD 154
Next Page